"ATS 2018 - Treatment of Severe Eosinophilic Asthma With IL-5 Antagonists"
Linda Rogers, MD, associate professor of medicine, pulmonary, critical care and sleep medicine at the Icahn School of Medicine at Mount Sinai, discusses the background and findings of her presentation entitled A Real World, Single Center Experience of Treatment of Severe Eosinophilic Asthma with IL-5 Antagonists; Mepolizumab and Reslizumab. “Many patients with asthma have eosinophilic inflammation and for the vast majority of those patients, their disease can be adequately controlled with inhaled cortical steroids. However, there is a subset of those patients, probably about five to ten percent of patients with asthma in whom inhaled cortical steroids including high doses, are not adequate to control eosinophilic inflammation in their airways.”
- Linda Rogers, MD, Associate Professor, Medicine, Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai
Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its KindDec 04, 2018 View All Press Releases